Dr. Tse Wen Chang, Chairman and CEO of Immunwork, and Dr. Art Hsing-Mao Chu, CEO of T-E Meds, have been invited to World ADC Asia 2024 in Korea.
They will share updates on our innovative tech platforms and drug candidates, with a special focus on our ADC technologies. Dr. Chu will present “Exploring ADCs With Site-Specific Conjugation, DAR of 8 or 12, & Payloads with Dual Drugs to Turbocharge ADC Innovation,” covering:
- “CHO-TEM” technology combining CHO Pharma’s glycan modification and T-E Meds’ “Drug Bundles.”
- Producing homogeneous ADCs with high DAR (8 or 12) and dual drugs.
- Straightforward manufacturing process with great reaction yield.
World ADC Asia, the premier ADC conference, gathers top industry leaders to discuss the future of ADC development. Join us in Korea!
